ClinicalTrials

1		Completed Has Results	Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema	Head and Neck Neoplasms Head and NeckLymphedema Head and Neck Cancer	Device: Head and neck garments for pneumatic compression device Drug: NIRFLI with ICG	UT Health Science Center at Houston Houston, Texas, United States
2		Completed Has Results	Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients WithHead and Neck Cancer	Head and Neck Neoplasms Mucositis	Drug: Brilacidin Other: Placebo	Gilbert, Arizona, United States Lakeland, Florida, United States Columbus, Georgia, United States (and 13 more...)
3		Terminated Has Results	Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer	Head and Neck Cancer	Drug: erlotinib hydrochloride Drug: pemetrexed disodium Procedure: quality-of-life assessment Radiation: intensity-modulated radiation therapy	UNC Linberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States
4		Terminated Has Results	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of theHead and Neck (SCCHN )	Head and Neck Neoplasms	Drug: Patritumab Drug: Cetuximab Drug: Cisplatin (and 2 more...)	Institut Jules Bordet Brussels, Belgium Univeristair Ziekenhuis Antwerpen Edegem, Belgium UZ Leuven Leuven, Belgium (and 31 more...)
5		Active, not recruiting Has Results	Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)	Head and NeckSquamous Cell Cancer	Biological: pembrolizumab Drug: methotrexate Drug: docetaxel Biological: cetuximab
6		Completed Has Results	Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery	Head and NeckSquamous Cell Carcinoma Recurrent Head and NeckCarcinoma	Biological: Cetuximab Other: Laboratory Biomarker Analysis Drug: Tivantinib	Mayo Clinic in Arizona Scottsdale, Arizona, United States City of Hope Comprehensive Cancer Center Duarte, California, United States USC / Norris Comprehensive Cancer Center Los Angeles, California, United States (and 21 more...)
7		Completed Has Results	Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients	Head and Neck Cancer Acute Pain Postoperative Pain	Drug: Gabapentin Drug: Placebo	Washington University School of Medicine Saint Louis, Missouri, United States
8		Completed Has Results	Use of the Passy Muir Swallowing Self Trainer	Stroke Brain Injury Head and Neck Cancer	Device: Dysphagia retraining with device	James Madison University Harrisonburg, Virginia, United States
9		Terminated Has Results	BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer	FGFR Gene Amplification FGFR1 Gene Amplification FGFR2 Gene Amplification (and 7 more...)	Drug: BGJ398	University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
10		Terminated Has Results	Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer	Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma (and 25 more...)	Radiation: Stereotactic Body Radiation Therapy Device: Positron Emission Tomography Device: Computed Tomography Other: Quality-of-Life Assessment	University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
11		Completed Has Results	Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer	Recurrent or Metastatic Head and NeckCarcinoma	Drug: Vinflunine Drug: Methotrexate	Institut de Recherche Pierre Fabre Toulouse, France
12		Active, not recruiting Has Results	Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer	Carcinoma, Squamous Cell of Head and Neck	Drug: Cetuximab Drug: Cisplatin/Carboplatin Drug: 5-fluorouracil	Please contact the Merck KGaA Communication Center Darmstadt, Germany
13		Terminated Has Results	Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy	Head and NeckSquamous Cell Carcinoma	Drug: Buparlisib Drug: Buparlisib matching Placebo Drug: Paclitaxel	Highlands Oncology Group Fayetteville, Arkansas, United States Dana Farber Cancer Institute IRB Boston, Massachusetts, United States Washington U School of Medicine Center for Clinical Studies SC - BKM120H2201 Saint Louis, Missouri, United States (and 55 more...)
14		Completed Has Results	A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin	Thyroid Neoplasm	Drug: Valproic Acid Drug: Liothyronine Sodium	National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
15		Completed Has Results	Pioglitazone in Thyroid Cancers	Thyroid CancersThat Contain the PAX8-PPARgamma Fusion Gene	Drug: Pioglitazone	University of Colorado Aurora, Colorado, United States University of Michigan Ann Arbor, Michigan, United States University of Pennsylvania Philadelphia, Pennsylvania, United States University of Texas MD Anderson Cancer Center Houston, Texas, United States
16		Completed Has Results	Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer	Thyroid Cancer	Drug: Temsirolimus and Sorafenib	Memorial Sloan-Kettering at Basking Ridge Basking Ridge, New Jersey, United States Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York, United States Memorial Sloan Kettering Cancer Center New York, New York, United States (and 2 more...)
17		Completed Has Results	Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer	Differentiated Thyroid Cancer	Drug: Selumetinib Drug: Placebo Drug: Radioactive Iodine Therapy	Research Site Birmingham, Alabama, United States Research Site Little Rock, Arkansas, United States Research Site Los Angeles, California, United States (and 42 more...)
18		Completed Has Results	Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer	Recurrent Salivary Gland Cancer Stage IVA Salivary Gland Cancer Stage IVB Salivary Gland Cancer Stage IVC Salivary Gland Cancer	Drug: eribulin mesylate	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
19		Terminated Has Results	CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer	Thyroid Neoplasms Poorly Differentiated and Undifferentiated Thyroid Cancer Differentiated Thyroid Cancer	Drug: CUDC-907	National Institutes of Health Clinical Center Bethesda, Maryland, United States
20		Completed Has Results	Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer	Esophageal Cancer Gastroesophageal Junction Cancer	Drug: Sorafenib, administered orally Procedure: CT/MRI	Memorial Sloan Kettering Cancer Center New York, New York, United States
21		Completed Has Results	BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer	Esophageal Cancer Gastric Cancer	Drug: Cetuximab,Paclitaxel, Carboplatin	Brown University Oncology Group Providence, Rhode Island, United States
22		Terminated Has Results	Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer	Advanced Cancer Breast Cancer Gastric Cancer (and 2 more...)	Drug: Pembrolizumab Drug: Trastuzumab Drug: ado-trastuzumab emtansine Drug: Cetuximab	Western Regional Medical Center/Cancer Treatment Center of America Goodyear, Arizona, United States
23		Active, not recruiting Has Results	Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers	Liver Cancer Anxiety Disorder Depression (and 7 more...)	Other: Early palliative care	UC San Diego Moores Cancer Center La Jolla, California, United States Queen's Medical Center Honolulu, Hawaii, United States University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States (and 20 more...)
24		Terminated Has Results	A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)	Medullary Thyroid Carcinoma	Drug: Bortezomib Drug: Vandetanib	National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
25		Completed Has Results	Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	Adenocarcinoma of the Gastroesophageal Junction Esophageal Undifferentiated Carcinoma Gastric Adenocarcinoma (and 14 more...)	Other: Laboratory Biomarker Analysis Drug: Oxaliplatin Drug: Pralatrexate	Roswell Park Cancer Institute Buffalo, New York, United States Rochester General Hospital Rochester, New York, United States
26		Active, not recruiting Has Results	A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Biological: pembroliziumab Drug: paclitaxel
27		Completed Has Results	Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy	Thyroid Neoplasms Goiter, Nodular Thyroid Nodule (and 2 more...)	Procedure: Superficial Cervical Plexus Block Procedure: Local Wound Infiltration Drug: 0.9% saline Drug: Marcaine	University of Chicago Medical Center Chicago, Illinois, United States
28		Active, not recruiting Has Results	Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer	Hereditary Thyroid Gland Medullary Carcinoma Multiple Endocrine Neoplasia Type 2A Multiple Endocrine Neoplasia Type 2B (and 6 more...)	Other: Laboratory Biomarker Analysis Other: Pharmacological Study Drug: Sorafenib Tosylate	Washington University School of Medicine Saint Louis, Missouri, United States Duke University Medical Center Durham, North Carolina, United States Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
29		Completed Has Results	A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer	Lung Cancer Esophageal Cancer		University of Virginia Charlottesville, Virginia, United States
30		Active, not recruiting Has Results	Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)	Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Gastric CancerThird Line	Drug: Avelumab Drug: Irinotecan Drug: Paclitaxel Other: Best Supportive Care (BSC)	Rocky Mountain Cancer Centers 1800 Williams Street, Suite 100 Denver, Colorado, United States Rocky Mountain Cancer Centers, LLP 3676 Parker Blvd #350 Pueblo, Colorado, United States Advanced Medical Specialties 8940 North Kendall Drive, Suite 300E Miami, Florida, United States (and 72 more...)
31		Terminated Has Results	Metabolomic and BH3 Profiling of EsophagealCancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy	Esophageal Cancer Esophageal Adenocarcinoma Esophageal Squamous Cell Cancer (and 2 more...)	Other: Chemoradiotherapy Procedure: Esophagectomy	National Institutes of Health Clinical Center Bethesda, Maryland, United States
32		Completed Has Results	Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Ovary Cancer Cervix Cancer Endometrium Cancer (and 4 more...)	Drug: Tisotumab vedotin (HuMax-TF-ADC)	MD Anderson Cancer Center Houston, Texas, United States Institut Jules Bordet Bruxelles, Brussels, Belgium Universitaire Ziekenhuizen Leuven Leuven, Flemish Brabant, Belgium (and 13 more...)
33		Completed Has Results	A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Drug: Ramucirumab Drug: Paclitaxel	City of Hope National Medical Center Duarte, California, United States University of Kansas Medical Center Westwood, Kansas, United States Dana Farber Cancer Institute Boston, Massachusetts, United States (and 49 more...)
34		Terminated Has Results	Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma	Biological: CRS-207 Biological: Pembrolizumab	UCLA Medical Center Los Angeles, California, United States University of Colorado Aurora, Colorado, United States University of Chicago Medical Center Chicago, Illinois, United States (and 5 more...)
35		Completed Has Results	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers	Cervical Cancer Oropharyngeal Cancer Vaginal Cancer (and 2 more...)	Drug: Fludarabine Drug: Cyclophosphamide Biological: Young TIL Drug: Aldesleukin	National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
36		Active, not recruiting Has Results	A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma	Metastatic Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Drug: Ramucirumab Drug: Placebo Drug: S-1 (and 2 more...)	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Akashi, Japan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bunkyo-Ku, Japan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan (and 31 more...)
37		Completed Has Results	The Passy Muir Swallowing Self Training Device	Oropharyngeal Dysphagia	Device: Vibrotactile stimulation	James Madison University and Rockingham Memorial Hospital Harrisonburg, Virginia, United States
38		Completed Has Results	Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Neoplasms	Drug: CC-486	Winship Cancer Institute of Emory University Atlanta, Georgia, United States University of Chicago Chicago, Illinois, United States Dana Farber Cancer Institute Boston, Massachusetts, United States (and 22 more...)
39		Completed Has Results	NBI to Detect Post-RT Mucosal Residual NPC	Nasopharyngeal Carcinoma	Device: Laryngoscope with NBI system	Pamela Youde Nethersole Eastern Hospital Hong Kong, Hong Kong